In-hospital clinical course and adverse events: Findings regarding major adverse cardiovascular events, escalation treatment, in-hospital stay, and bleeding complications are presented in Table 5.2. Patients under thrombolysis had better outcome than patients under unfractionated heparin alone. Major bleeding complications had a close relationship with venous puncture in both groups [10].

Follow-up and major adverse cardiovascular events: Follow-up was complete in 100 % of the cases (Table 5.2). Within the first 30 and 90 days the most important clinical finding was a pulmonary perfusion improvement in alteplase plus enoxaparin group compared with unfractionated heparin alone. Although a trend to major incidence of major adverse cardiovascular events in unfractionated heparin group was observed, these clinical findings had statistical significance until day 180, including a better right ventricular remodeling. Global mortality was another relevant clinical finding (Table 5.2) [10].